Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

141. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Gralnek I M, Dulai G S, Fennerty M B, Spiegel B M CRD summary This review concluded that while there was a statistically significant (...) improvement with esomeprazole compared with other proton-pump inhibitors in healing and symptoms, the clinical benefit was modest and may be more important in severe than mild erosive esophagitis. The overall conclusion appears reliable but the conclusion about the influence of disease severity should be viewed with caution. Authors' objectives To assess the effect of esomeprazole compared with other proton- pump inhibitors (PPIs) on healing rates, symptom relief and adverse events in the treatment

DARE.2006

142. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori

A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori Wang X, Fang J Y, Lu R, Sun D F CRD summary The authors concluded that esomeprazole-based triple therapy may be as effective as omeprazole-based therapy (...) in eradicating Helicobacter pylori, and was well tolerated. There were limitations to this review that appear to undermine the reliability of these conclusions. Authors' objectives To compare the effects of esomeprazole-based therapy and alternative proton-pump inhibitor (PPI)-based therapy on Helicobacter pylori (H. pylori) eradication rates. Searching MEDLINE, EMBASE, the Cochrane Library and the Chinese Biomedical Database were searched from 2000 to 2005 using the reported search terms. In addition

DARE.2006

143. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux

A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux Sen P, Georgalas C, Bhattacharyya A K CRD summary This review assessed the efficacy of proton-pump inhibitors in the treatment of laryngopharyngeal reflux in adults. The authors concluded (...) that there was insufficient evidence on which to base conclusions regarding the effectiveness of the intervention, and further randomised trials are required. Despite limitations to this review, the authors' cautious conclusions are justified give the data available. Authors' objectives To assess the efficacy of proton-pump inhibitors (PPIs) in the treatment of laryngopharyngeal reflux in adults. Searching MEDLINE (from 1966), EMBASE (from 1980) and the Cochrane Controlled Trials Register were searched up to October 2004

DARE.2006

144. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review

Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Karkos P D, Wilson J A CRD summary This review evaluated the use of proton-pump inhibitors (PPIs) for the treatment of laryngopharyngeal reflux and found no evidence to demonstrate superiority of PPIs over placebo (...) . Limitations in the reporting of the included studies and review methodology mean that it is not possible to comment on the robustness of the evidence presented or the authors' conclusion. Authors' objectives To evaluate the treatment of suspected laryngopharyngeal reflux (LPR) symptoms with proton-pump inhibitors (PPIs). Searching MEDLINE, EMBASE, CINAHL and the Cochrane Library were searched for studies published in any language; the search terms were reported. References from relevant articles were also

DARE.2006

145. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials

Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials Qadeer M A, Phillips C O, Lopez A R, Steward D L, Noordzij J P, Wo J M, Suurna M, Havas T, Howden C W, Vaezi M F CRD summary (...) This review compared proton-pump inhibitors (PPIs) with placebo for treating suspected gastroesophageal reflux disease-related chronic laryngitis in adults. The authors concluded that PPI therapy had a modest but non significant effect over placebo. This was a well-conducted systematic review and the conclusion appears reliable. Authors' objectives To evaluate the efficacy of proton-pump inhibitors (PPIs) for treating suspected gastroesophageal reflux disease (GERD)-related chronic laryngitis. Searching

DARE.2006

146. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs

Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Edwards S J, Lind T, Lundell L CRD summary This review compared the effectiveness of esomeprazole (...) with other standard-dose proton-pump inhibitors for the treatment of reflux oesophagitis, and found that 40 mg esomeprazole is the most effective treatment currently available. Overall, the findings of the review appear to be supported by the data, but caution is advised given the levels of unexplained statistical variation detected between the studies. Authors' objectives To compare the effectiveness of esomeprazole with other proton- pump inhibitors (PPIs) for the treatment of reflux oesophagitis

DARE.2006

147. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses

Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro A G, Quitadamo M, Merla A, Fiorella S, Leandro G CRD summary This review assessed the effects (...) of proton-pump inhibitor (PPI) regimens on bleeding ulcers. The authors concluded that endotherapy plus either PPIs or H2-receptor antagonists are indicated for nonbleeding ulcers, but there are insufficient data to support this combination for Forrest 1A or 1B ulcers. This was generally a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To assess the effects of different proton-pump inhibitor (PPI) regimens on bleeding ulcers, and to determine the effects according

DARE.2005

148. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials

Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Mcquaid K R, Laine L CRD summary This review assessed proton-pump inhibitors for the relief of heartburn within 1 to 2 days. The authors concluded (...) that proton pump inhibitors may improve symptoms within 24 hours, but most patients will not experience relief in the first 1 or 2 days. Apart from the limited search, this was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of proton-pump inhibitors (PPIs) for heartburn relief within the first 1 to 2 days of treatment. Searching MEDLINE (1966 to June 2004) and EMBASE (1980 to June 2004) were searched without language restrictions; the search

DARE.2005

149. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis

Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis Wang W H, Huang J Q, Zheng G F (...) , Wong W M, Lam S K, Karlberg J, Xia H H, Fass R, Wong B C CRD summary This review addressed the usefulness of initial treatment with a proton-pump inhibitor (PPI) as a method of diagnosing gastroesophageal reflux disease (GERD) in patients with noncardiac chest pain. The review was well conducted and clearly reported. The authors' conclusion, that initial treatment with PPI is a valid method of testing for GERD, is likely to be reliable. Authors' objectives To evaluate the accuracy

DARE.2005

150. Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication

Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication Janssen M J, Laheij R J, De Boer W A, Jansen J B CRD summary This review assessed the effects of pre-treatment with a proton-pump inhibitor on triple and quadruple (...) therapies for Helicobacter pylori eradication. The authors concluded that pre-treatment had no effect on Helicobacter pylori eradication. Differences between the studies mean that the reliability of the results is uncertain. Authors' objectives To evaluate the effect of pre-treatment with a proton-pump inhibitor (PPI) on Helicobacter pylori (H. pylori) eradication. Searching The Cochrane Controlled Trials Register, MEDLINE, Current Contents and CINAHL were searched without language restrictions

DARE.2005

151. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Gisbert J P, Pajares J M CRD summary This review concluded that prolonging therapy with proton-pump inhibitor (PPI) after 1-week (...) triple therapy with PPI and two antibiotics is not necessary to induce ulcer healing. The conclusion is weakened by poor reporting of the methods and limited details of the study participants. Authors' objectives To determine the efficacy of 1-week combination of proton-pump inhibitor (PPI) and two antibiotics on ulcer healing; and to determine whether 1-week PPI-based triple therapy is sufficient to heal peptic ulcer. Searching MEDLINE, EMBASE, CINAHL and the Cochrane Library (Issue 3, 2004) were

DARE.2005

152. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease

Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor (...) of gastro-oesophageal reflux disease (GORD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with a history of GORD and who had depended on a PPI for at least 3 months. Setting The setting was primary care and a hospital. The economic study was performed in the UK. Dates to which data relate The effectiveness evidence and most resource use data were gathered between June 1997 and August 2001. The price year was 2001. Source of effectiveness

NHS Economic Evaluation Database.2005

153. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Hughes D, Bodger K, Bytzer P, De Herdt D, Dubois D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several on-demand maintenance therapies with oral proton-pump inhibitors (PPIs) in patients with endoscopy-confirmed non-erosive reflux disease (NERD). The PPIs studied were esomeprazole 20 mg, lansoprazole 15 mg, omeprazole 10 and 20 mg

NHS Economic Evaluation Database.2005

154. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK

Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Remak E, Brown R E, Yuen C, Robinson A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) to treat gastro-oesophageal reflux disease (GORD). Seven PPIs were compared. These were esomeprazole, lansoprazole capsules, lansoprazole oro-dispersible tablets, omeprazole (generic and branded), pantoprazole and rabeprazole. Type of intervention

NHS Economic Evaluation Database.2005

155. 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan

'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S (...) on a first-line proton-pump inhibitor (PPI), lansoprazole 30 mg/day (LAN), for 8 weeks (plus a further 12 weeks for unhealed patients). The other was a step-up approach in which patients started with a histamine H2-receptor antagonist (H2RA), ranitidine 300 mg/day (RAN), for 8 weeks and then switched to LAN in case of failure. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients

NHS Economic Evaluation Database.2005

156. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?

Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Lee T J, Fennerty M B, Howden C W CRD summary This review assessed alternatives to continuous proton-pump inhibitor (PPI) treatment for gastrooesophageal reflux disease. The authors (...) concluded that evidence supported on-demand PPI treatment of endoscopy-negative reflux disease, but there was less support for on-demand treatment of erosive oesophagitis. Incomplete reporting of review methods and limited information on study outcomes and results make the reliability of the conclusions uncertain. Authors' objectives To assess the effects of alternatives to continuous proton-pump inhibitors (PPIs) for the long-term treatment of gastrooesophageal reflux disease (GERD). Searching MEDLINE

DARE.2004

157. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics

Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Numans M E, Lau J, de Wit N J, Bonis P A CRD summary (...) This review assessed the accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment in the diagnosis of gastroesophageal reflux disease (GERD). The authors concluded that a response to short-term treatment with PPIs does not accurately diagnose GERD as defined by traditional objective criteria. The authors' conclusions are likely to be reliable. Authors' objectives To determine the diagnostic accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment as an indicator

DARE.2004

158. Effectiveness of proton pump inhibitors in nonerosive reflux disease

Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Dean B B, Gano A D, Knight K, Ofman J J, Fass R CRD summary This review assessed the use of proton-pump inhibitors (PPIs) to relieve the symptoms of nonerosive reflux disease (NERD). The authors concluded that PPIs have a lesser effect in NERD than in erosive oesophagitis, and that symptoms (...) tended to improve throughout the 4-week period. Insufficient data were presented to assess the appropriateness of pooling the studies, hence any conclusions may not be reliable. Authors' objectives To assess the effectiveness of proton-pump inhibitors (PPIs) for the relief of symptoms of nonerosive reflux disease (NERD), and also to assess the effects of PPIs in patients with NERD compared with patients with erosive oesophagitis (EE). Searching MEDLINE and HealthSTAR were searched for studies

DARE.2004

159. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding

Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Erstad B L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of adjunctive oral and intravenous proton-pump inhibitor (PPI) therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalisation. Four clinical scenarios were considered. Scenario 1 was diagnostic endoscopy and oral PPI therapy (40 mg twice daily of omeprazole or the equivalent dose of another PPI for 5 days). Scenario 2

NHS Economic Evaluation Database.2004

160. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis Moayyedi P, Delaney B C, Vakil N, Forman D, Talley N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) in adult patients with nonulcer dyspepsia (NUD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of adult patients with symptoms of dyspepsia, negative findings on endoscopy

NHS Economic Evaluation Database.2004